Taren Grom, Editor
NOTE: The content below contains the first few paragraphs of the printed article and the titles of the sidebars and boxes, if applicable.
2014 — Year in Preview
From the ACA to social media, industry executives are providing their predictions on what’s hot for 2014.
For this special annual issue of PharmaVOICE, we invited dozens of industry experts to provide their predictions on the emerging and current trends they expect to impact the life-sciences industry in the near future. We are excited to share their insights with you in this Year in Preview issue. Throughout this issue, which we have broken down into three main sections — corporate, R&D, and commercialization — our experts representing all types of companies and disciplines discuss the shifts that are taking place throughout the industry, including the shift to a patient-centric ecosystem, R&D trends, and the factors that are impacting commercialization from a three-pronged perspective: patients, payers, and physicians. To kick off this special issue, thanks to our friends at PwC’s Health Research Institute, here are some key drivers to watch for in 2014. According to its annual report, Medical Cost Trend: Behind the Numbers: • Healthcare inflation in the United States is projected to dip to 6.5% in 2014. The ongoing slowdown in the healthcare growth rate defies historical post-recession patterns and is likely to be sustained even as the Affordable Care Act (ACA) adds millions more newly insured Americans to the health system next year. • The decline in spending growth is a signal of progress in the quest to bend the cost curve. At the same time, the slowdown presents financial challenges for the industry as it attempts to navigate in a rapidly changing environment. According to HRI, structural changes within the industry are helping to contain costs and deliver care more efficiently. Consumers, meanwhile, who are paying a greater share of the cost, are making spending adjustments. Many are delaying care, using fewer services, and choosing less expensive options such as retail clinics, urgent care centers, and mobile health devices. • Health organizations that already have been hurt by a squeeze on reimbursement and a recession hangover should brace for additional financial pressure. Uncertainty about the impact of ACA implementation and what to expect from a largely unknown, newly insured population are manifested in seemingly contradicting themes: a declining medical cost trend and rising insurance premiums, particularly in the individual market. • Major employers are beginning to contract directly with big-name health systems to tackle expensive and complex procedures for employees, such as heart surgery and spinal fusion. According to PwC’s Touchstone Survey, 33% of businesses are considering high-performance networks over the next year. Early data suggest this could mean as much as a 25% reduction in costs. Wishing all a healthy and happy 2014! We look forward to hearing from all of you in the coming year with your thoughts and insights. Their Word Denise Myshko Managing Editor New types of partnerships will be required to address the industry’s innovation gap. Alliances, collaborations, and consortia will continue to drive new therapies in the future. Robin Robinson Senior Editor In 2014, the industry will collaborate with all stakeholders across the healthcare spectrum as well as focus its commercialization process toward better meeting patients’ needs. Kim Ribbink Features Editor Signs point to continued global expansion in pharma, and ensuring quality and compliance in less established markets must be a priority. Publisher Lisa Banket Editor Taren Grom Creative Director Marah Walsh Managing EDitor Denise Myshko Senior EDitor Robin Robinson features EDitor Kim Ribbink design associate Ariel Medel national account managerS Trish Kane Cathy Tracy WEBCAST?NETWORK?PRODUCER Daniel Limbach CIRCULATION Assistant Kathy Deiuliis Copyright 2013 by PharmaLinx LLC, Titusville, NJ Printed in the U.S.A. Volume Thirteen, Number Ten PharmaVoice (ISSN: 1932961X) is published monthly except joint issues in July/Aug. and Nov./Dec., by PharmaLinx LLC, P.O.?Box 327, Titusville, NJ 08560. Periodicals postage paid at Titusville, NJ 08560 and additional mailing offices. Postmaster: Send address changes to PharmaVoice, P.O. Box 292345, Kettering, OH 45429-0345. PharmaVoice Coverage and Distribution: Domestic subscriptions are available at $190 for one year (10 issues). Foreign subscriptions: 10 issues US$360. Contact PharmaVoice at P.O.?Box 327, Titusville, NJ 08560. Call us at 609.730.0196 or FAX your order to 609.730.0197. Contributions: PharmaVoice is not responsible for unsolicited contributions of any type. Unless otherwise agreed in writing, PharmaVoice retains all rights on material published in PharmaVoice for a period of six months after publication and reprint rights after that period expires. E-mail: firstname.lastname@example.org. Change of address: Please allow six weeks for a change of address. Send your new address along with your subscription label to PharmaVoice, P.O. Box 292345, Kettering, OH 45429-0345. Call us at 800.607.4410 or FAX your change to 937.890.0221. E-mail: email@example.com. Important notice: The post office will not forward copies of this magazine. PharmaVoice is not responsible for replacing undelivered copies due to lack of or late notification of address change. Advertising in PharmaVoice: To advertise in PharmaVoice please contact our Advertising Department at P.O.?Box 327, Titusville, NJ 08560, or telephone us at 609.730.0196. E-mail: firstname.lastname@example.org. Volume 13 • Number 10 Letters Send your letters to email@example.com. Please include your name, title, company, and business phone number. Letters chosen for publication may be edited for length and clarity. All submissions become the property of PharmaLinx LLC. > Innovation > Gaming > Public-Private Partnerships > Risk-Based Monitoring > Affordable Care Act > Breakthrough Therapy Designation > C-Suite: Clinical Services > Commercialization > Beyond BRIC > Showcase Feature — Social Media > Device Watch — Clinical Development